van Oers MH - Search Results

1

Glucocerebrosidase genotype of Gaucher patients in The Netherlands: limitations in prognostic value.

Boot RG, Hollak CE, Verhoek M, Sloof P, Poorthuis BJ, Kleijer WJ, Wevers RA, van Oers MH, Mannens MM, Aerts JM, van Weely S. Boot RG, et al. Among authors: van oers mh, van weely s. Hum Mutat. 1997;10(5):348-58. doi: 10.1002/(SICI)1098-1004(1997)10:5<348::AID-HUMU3>3.0.CO;2-B. Hum Mutat. 1997. PMID: 9375849

2

Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.

Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH. Hollak CE, et al. Among authors: van oers mh, van weely s. Lancet. 1995 Jun 10;345(8963):1474-8. doi: 10.1016/s0140-6736(95)91037-9. Lancet. 1995. PMID: 7769902 Clinical Trial.

3

Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Hollak CE, van Weely S, van Oers MH, Aerts JM. Hollak CE, et al. Among authors: van oers mh, van weely s. J Clin Invest. 1994 Mar;93(3):1288-92. doi: 10.1172/JCI117084. J Clin Invest. 1994. PMID: 8132768 Free PMC article.

4

Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease.

Hollak CE, Evers L, Aerts JM, van Oers MH. Hollak CE, et al. Among authors: van oers mh. Blood Cells Mol Dis. 1997 Aug;23(2):201-12. doi: 10.1006/bcmd.1997.0137. Blood Cells Mol Dis. 1997. PMID: 9236158

5

Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease.

Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, van Oers MH. Hollak CE, et al. Among authors: van oers mh. Am J Med. 1997 Sep;103(3):185-91. doi: 10.1016/s0002-9343(97)00134-4. Am J Med. 1997. PMID: 9316550

6

Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature.

de Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, Boot RG, Aerts JF, Maas M, Vom Dahl S, Hollak CE. de Fost M, et al. Among authors: van oers mh. Ann Hematol. 2008 Jun;87(6):439-49. doi: 10.1007/s00277-008-0441-8. Epub 2008 Feb 15. Ann Hematol. 2008. PMID: 18274746 Free PMC article.

7

Treatment of Gaucher's disease.

Hollak CE, Aerts JM, van Oers MH. Hollak CE, et al. Among authors: van oers mh. N Engl J Med. 1993 May 27;328(21):1565-6; author reply 1567. N Engl J Med. 1993. PMID: 8479498 No abstract available.

8

[The treatment of Gaucher's disease in The Netherlands using enzyme substitution therapy].

Hollak CE, van Oers MH, Maaswinkel P, Aerts JM, Goudsmit R. Hollak CE, et al. Among authors: van oers mh. Ned Tijdschr Geneeskd. 1996 May 11;140(19):1011-3. Ned Tijdschr Geneeskd. 1996. PMID: 8684492 Review. Dutch. No abstract available.

9

Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy.

Hollak CE, Levi M, Berends F, Aerts JM, van Oers MH. Hollak CE, et al. Among authors: van oers mh. Br J Haematol. 1997 Mar;96(3):470-6. doi: 10.1046/j.1365-2141.1997.d01-2076.x. Br J Haematol. 1997. PMID: 9054650 Free article.

10

Alglucerase: practical guidance on appropriate dosage and administration in patients with Gaucher disease.

Hollak CE, Aerts JM, van Oers MH. Hollak CE, et al. Among authors: van oers mh. BioDrugs. 1998 Jan;9(1):11-23. doi: 10.2165/00063030-199809010-00002. BioDrugs. 1998. PMID: 18020553

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters